Effect of Unani medicine Khamira Gawzaban Sada in Zuâ??f al-DimÄ?gh (Cerebro-asthenia)

Phase 2

• Conditions: Health Condition 1: G31- Other degenerative diseases of nervous system, not elsewhere classifiedHealth Condition 2: null- Zuâ??f al-DimÄ?gh (Cerebro-asthenia)

• Registration Number: CTRI/2018/09/015692
• Lead Sponsor: Central Council for Research in Unani Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

The patients fulfilling the following criteria will be included in this study:

1. Patients of any sex in the age group 19-70 years

2. Patients of Zuâ??f al-DimÄ?gh (Cerebro-asthenia) having:

ï?§Subjective complaints of cognitive impairment

ï?§MMSE score of 10-23 representing mild to moderate cognitive impairment

Exclusion Criteria

1.Clinical presentation and/or history of any significant organic neurological diseases including space occupying lesions, stroke, head injury, seizure, and mental retardation

2.Patients with impairment of speech, hearing and vision, which can impede the interview for MMSE and QOL assessment

3.Known cases of hypothyroidism or hyperthyroidism

4.Vitamin B12 deficiency

5.Patients on Psychotropic Drugs

6.Clinical presentation and/or history of a chronic disease that requires long-term treatment, e.g., DM, tuberculosis, HIV infection, syphilis, CVD, pulmonary disease, CKD, chronic liver disease, or any other serious and/or unstable medical condition that, in the opinion of the investigator, could expose the patients to undue risk of a significant adverse event or interfere with assessment of safety or efficacy during the course of the trial

7.Pregnant and lactating women

8.H/o Addiction (alcohol, drugs)

9.H/o Hypersensitivity to the study drug or any of its ingredients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Zuâ??f al-DimÄ?gh (Cerebro-asthenia) <br/ ><br> <br/ ><br>Timepoint: 6 weeks <br/ ><br> <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessmentTimepoint: at baseline and at the end of treatment